Patents by Inventor Robert Jan BENSCHOP
Robert Jan BENSCHOP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10913793Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.Type: GrantFiled: October 25, 2019Date of Patent: February 9, 2021Assignee: Eli Lilly and CompanyInventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
-
Patent number: 10577415Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.Type: GrantFiled: April 26, 2018Date of Patent: March 3, 2020Assignee: Eli Lilly and CompanyInventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng Wu
-
Publication number: 20200048340Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
-
Patent number: 10501536Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.Type: GrantFiled: October 24, 2017Date of Patent: December 10, 2019Assignee: Eli Lilly and CompanyInventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
-
Publication number: 20180319880Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.Type: ApplicationFiled: April 26, 2018Publication date: November 8, 2018Inventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng WU
-
Publication number: 20180291093Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).Type: ApplicationFiled: October 30, 2015Publication date: October 11, 2018Applicant: Eli Lilly and CompanyInventors: Robert Jan Benschop, Rohn L Millican, JR., Barrett Allan, Catherine Brautigam Beidler
-
Publication number: 20180118821Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.Type: ApplicationFiled: October 24, 2017Publication date: May 3, 2018Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel
-
Patent number: 9708402Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: GrantFiled: May 18, 2016Date of Patent: July 18, 2017Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Publication number: 20170073403Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: ApplicationFiled: November 2, 2016Publication date: March 16, 2017Applicant: Eli Lilly and CompanyInventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
-
Patent number: 9505838Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: GrantFiled: June 4, 2015Date of Patent: November 29, 2016Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
-
Publication number: 20160251430Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: ApplicationFiled: May 18, 2016Publication date: September 1, 2016Applicant: Eli Lilly and CompanyInventors: Barrett ALLAN, Robert Jan BENSCHOP, Jirong LU
-
Patent number: 9359448Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: GrantFiled: April 16, 2013Date of Patent: June 7, 2016Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Publication number: 20150259415Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: ApplicationFiled: June 4, 2015Publication date: September 17, 2015Applicant: ELI LILLY AND COMPANYInventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
-
Patent number: 9073991Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: GrantFiled: June 7, 2011Date of Patent: July 7, 2015Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
-
Publication number: 20130280256Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: ApplicationFiled: April 16, 2013Publication date: October 24, 2013Applicant: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Publication number: 20110305711Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: ApplicationFiled: June 7, 2011Publication date: December 15, 2011Applicant: ELI LILLY AND COMPANYInventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING